PLx Pharma (PLXP) Stock Rating Upgraded by ValuEngine
PLx Pharma (NASDAQ:PLXP) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Monday.
Separately, Zacks Investment Research cut shares of PLx Pharma from a “buy” rating to a “hold” rating in a report on Saturday, August 19th.
PLx Pharma (PLXP) opened at $6.65 on Monday. The company has a current ratio of 8.99, a quick ratio of 8.88 and a debt-to-equity ratio of 0.56. PLx Pharma has a twelve month low of $5.60 and a twelve month high of $22.00.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of PLx Pharma during the third quarter valued at approximately $145,000. University of Texas Investment Managment Co. bought a new stake in PLx Pharma during the second quarter valued at approximately $385,000. Finally, Susquehanna International Group LLP bought a new stake in PLx Pharma during the second quarter valued at approximately $1,413,000. 21.87% of the stock is owned by hedge funds and other institutional investors.
PLx Pharma Company Profile
PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.
Receive News & Ratings for PLx Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.